Sabrina Serani

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high transfusion dependency.

The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in interventional oncology.

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target action date of March 2026.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk myelodysplastic syndrome treated with bexmarilimab.

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment resistance.

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients undergoing CAR T-cell therapy.

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this aggressive brain cancer.

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients, over nearly a decade.

Akeso initiates a pivotal trial for cadonilimab and lenvatinib, targeting advanced liver cancer resistant to PD-1 therapy, addressing urgent treatment needs.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for patients with H3 K27M mutation.

The FDA issued a complete response letter to the odronextamab application in follicular lymphoma, rejecting the drug for a second time in this patient population.

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering new treatment hope.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor cells.

UroGen Pharma's ENVISION trial reveals promising long-term efficacy of intravesical mitomycin for treating low-grade bladder cancer, offering a non-surgical option.

Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, enhancing response rates significantly.

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting future research.

FDA prioritizes review of liso-cel, a groundbreaking CAR T-cell therapy for relapsed marginal zone lymphoma, promising improved patient outcomes.

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting unmet clinical needs.

Trethera Corporation initiates a clinical trial for TRE-515, exploring its potential in oncology and autoimmune diseases while enhancing patient quality of life.

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing treatment decisions for advanced cancer patients.

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's side effects and improve patient outcomes.

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining treatment standards.

The KEYNOTE-426 trial confirms pembrolizumab plus axitinib's long-term effectiveness for advanced kidney cancer, revealing insights into predictive biomarkers for treatment response.

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach.

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast cancer, offering hope for patients.

Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization and combination therapy strategies.

FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and review process.